Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) is organized by ScientiaCME.

Release Date: March 05, 2019
Expiration Date: March 05, 2021

Target Audience:
The following healthcare professionals: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with hemophilia B.

Accreditation:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists:
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 0.75 hours (0.075 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-19-005-H01-P. ACPE Accreditation effective 03/12/19, expires 03/12/21. 

Program Description / Statement of Need:
In this online CME self-learning program:
Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia B is the same in all geographic regions, populations, and ethnic groups, affecting approximately 1 out of every 30,000 male births. The condition is diagnosed by measuring FIX activity, and patients with severe hemophilia have levels of 1% or less.

Patients with severe hemophilia B are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years, and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

This program is a learning activity focused on Hemophilia B and its complications, designed to bring healthcare providers up to date in their practice and give them a sense of coming changes to practice and the literature.

Program Objectives:
By the end of the session the participant will be able to:
• Describe the gene therapy and its anticipated impact on hemophilia B therapy
• List evidence-supported benefits of switching to extended half-life / dose-interval clotting factors and apply that knowledge to patient cases
• Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia B, and apply** them to patient cases
• Describe how immune modulation therapy may be used to induce immune tolerance to Factor IX inhibitors